Abstract
4-Aminopyridine (4-AP) is a K+ channel blocking agent that enhances nerve conduction through areas of demyelination by prolonging the duration of the action potential and increasing the safety factor for conduction. We have investigated the effects of 4-AP (24 mg total dose-intravenous) in 6 patients with spinal cord injury (3 complete, 3 incomplete) with the intent of overcoming central conduction block, or slowing, due to demyelination. Vital signs remained stable and only mild side effects were noted. The 3 patients with incomplete injuries all demonstrated enhanced volitional EMG interference patterns and one patient exhibited restored toe movements. The changes were reversed on drug washout. There were no changes in segmental reflex activities. These results are consistent with those obtained from 4-AP trials with animal models of spinal cord injury, showing modest therapeutic benefit attributable to enhanced central conduction.
Similar content being viewed by others
Article PDF
References
Holmes G (1906) On the relation between loss of function and structural change in focal lesions of the central nervous system, with special reference to secondary degeneration. Brain 29: 514–523.
Harrison B M, McDonald W I (1977) Remyelination after transient experimental compression of the spinal cord. Ann Neurol 1: 542–551.
Harrison B M (1980) Remyelination by cells introduced into a stable demyelinating lesion in the central nervous system. J Neurol Sci 46: 63–81.
Griffiths I R, McCulloch M C (1983) Nerve fibers in spinal cord impact injuries. 1. Changes in the myelin sheath during the initial five weeks. J Neurol Sci 58: 335–345.
Blight A R (1983) Axonal physiology of chronic spinal cord injury in the cat, intracellular recording in vitro. Neuroscience 10: 1471–1486.
Blight A R (1985) Delayed demyelination and macrophage invasion: A candidate for ‘secondary’ cell damage in spinal cord injury. Cent Nerv Sys Trauma 2: 299–315.
Gledhill R F, Harrison B M, McDonald W I (1973) Demyelination and remyelination after acute spinal cord compression. Exp Neurol 38: 482–487.
Waxman S G (1989) Demyelination in spinal cord injury. J Neurol Sci 91: 1–14.
Lemiegnan M, Millart H, Lamiable D, Molgo J, Lechat P (1986) Evaluation of 4-aminopyridine and 3-4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 304: 166–169.
Sherratt R M, Bostock H, Sears T A (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature (Lond) 283: 570–572.
Bostock H, Sears T A, Sherratt R M (1981) The effects of 4-aminopyridine and Tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol (Lond) 313: 301–315.
Targ E F, Kocsis J D (1985) 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 328: 358–361.
Blight A R (1989) Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 22: 47–52.
Blight A R, Gruner J A (1987) Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 87: 145–159.
Blight A R, Toombs J P, Bauer M S, Widmer W R (1991) The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A Phase I clinical trial. J Neurotrauma 8: 103–119.
Stefoski D, Davis F A, Fitzsimmons W E, Luskin S S, Rush J, Parkhurst G W (1991) 4-Aminopyridine in multiple sclerosis: Prolonged administration. Neurology 41: 1344–1348.
Davis F A, Stefoski D, Rush J (1990) Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 27: 186–192.
Stefoski D, Davis F A, Faut M, Schauf C L (1987) 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21: 71–77.
Jones R E, Heron J R, Foster D H, Snelgar R S, Mason R J (1983) Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 60: 353–362.
Lundh H, Milsson O, Rosen I (1979) Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiat 42: 171–175.
Lundh H, Milsson O, Rosen I (1977) 4-Aminopyridine - A new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 40: 1109–1112.
Murray N M F, Newsom-Davis J (1981) Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31: 265–271.
Wesseling H, Lakke P J W F (1980) Observations with 4-aminopyridine in Huntington's chorea. IRCS J Med Sci 8: 322–333.
Sohn Y J, Uges D R A (1981) Pharmacokinetics and side effects of 4-aminopyridine. In: Proceedings of the seventh world congress of anaesthesiologists, Hamburg, Sept. 14-21, 1980. Excerpta Medica, Amsterdam.
Uges D R A, Sohn Y J, Greijdanus B, Scaf A H J, Agoston S (1982) 4-Aminopyridine kinetics. Clin Pharmacol Ther 31(5): 587–593.
Bowman W C, Savage A O (1981) Pharmacological actions of aminopyridines and related compounds. Rev Pure Applied Pharmacol Sci 2: 317–371.
Evenhuis J, Agoston S, Salt P J, De Lange A R, Wouthuyzen W, Erdmann W (1981) Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br J Anaesth 53: 567–570.
Davis F A, Schauf C L (1981) Approaches to the development of pharmacological interventions in multiple sclerosis. In: Waxman SG, Ritchie JM, editors. Demyelinating Disease: Basic and Clinical Electrophysi-ology. Raven Press, New York: 505–510.
Baker M, Bostock H, Grafe P, Matius P (1987) Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol (Lond) 383: 45–67.
Schauf C L, Davis F A (1974) Impulse conduction in multiple sclerosis: A theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry 37: 152–161.
Uges D R A, Huizinga T (1981) 4-Aminopyridine: Analysis of the substance and a method for the preparation of a solution for injection in man. Pharm Acta Helv 56: 158–162.
Lucas J T, Ducker T B (1978) Motor classification of spinal cord injuries with mobility, morbidity and recovery indices. Am Surg March: 151–158.
Hayes K C, Allatt R D, Wolfe D L, Kasai T, Hsieh J (1992) Reinforcement of subliminal flexion reflexes by transcranial magnetic stimulation of motor cortex in subjects with spinal cord injury. Electroenceph Clin Neurophysiol 85: 102–109.
Brown W F (1984) Conduction in abnormal nerve. In: The Physiological and Technical Basis of Electromyography. Butterworth & Co Ltd, London.
Jendrassik E (1983) Beitrage zur lehre von den Sehnenreflexen. Deutsch Arch Klin Med 33: 177–199.
Kawakita H, Kameyama O, Ogawa R, Hayes K C, Wolfe D L (1991) Reinforcement of motor evoked potentials by remote muscle contraction. J Electromyogr Kinesiol 1(2): 96–106.
Hayes K C, Allatt R D, Wolfe D L, Kasai T, Hsieh J T C (1991) Reinforcement of motor evoked potentials in patients with spinal cord injury. In: W J Levy, R Q Cracco, A T Barker, J Rothwell, editors. Magnetic Motor Stimulation: Basic Principles and Clinical Experience (EEG Suppl 43). Elsevier Science Publishers, BV.
Kocsis J D, Bowe C W, Waxman S G (1986) Different effects of 4-aminopyridine on sensory and motor fibers; Pathogenesis of paresthesias. Neurology 36: 177–120.
Hayes K C, Hsieh J T C, Wolfe D L, Blight A R, Potter P J, Delaney G A (in press) Effects of cooling on central conduction in normal subjects and patients with spinal cord injury. J Clin Neurophysiol.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hayes, K., Blight, A., Potter, P. et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Spinal Cord 31, 216–224 (1993). https://doi.org/10.1038/sc.1993.40
Issue Date:
DOI: https://doi.org/10.1038/sc.1993.40
Keywords
This article is cited by
-
Structure-activity relationship studies of four novel 4-aminopyridine K+ channel blockers
Scientific Reports (2020)
-
Dalfampridine in hereditary spastic paraplegia: a prospective, open study
Journal of Neurology (2015)
-
Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons
Neuroscience Bulletin (2011)
-
Molecular targets in spinal cord injury
Journal of Molecular Medicine (2005)